Introduction
Dantrolene is a skeletal muscle relaxant with a direct action on skeletal muscle. Chemically it is a hydantoin derivative (1-[(5-arylfurfurylidene)amino] hydantoin). The drug has been available in the U.K. for general use since June 1976. As with any new drug, the long-term safety of dantrolene has not been established. The development of lymphoproliferative disorders in association with another hydantoin derivative, phenytoin (diphenylhydantoin), has been well documented (Saltzstein and Ackerman, 1959; Hyman and Sommers, 1966; Gams, Neal and Conrad, 1968; Anthony, 1970 some of which were present in the sinuses. Bone marrow section confirmed the findings on sternal marrow examination. The overall appearances were those of a moderately well differentiated lymphocytic lymphoma.
Discussion
The development of lymphadenopathy as one of the less common side effects of phenytoin has long been recognized (Saltzstein and Ackerman, 1959) . Although originally regarded as a benign complication of hydantoin therapy, reversible on withdrawal of the drug, it was later clear that the use of this anticonvulsant could be associated with the development of fatal malignant lymphoma (Hyman and 0032-5473/80/0400-0261 $02.00 © 1980 The Fellowship of Postgraduate Medicine Case reports Sommers, 1966; Gams et al., 1968; Anthony, 1970) .
The evidence in the present case suggests that the patient developed a lymphoproliferative disorder which led to his death some 3 years after starting treatment with dantrolene. Of the other drugs involved in the treatment of this patient, tolbutamide is not known to induce lympho-proliferative disorders, although haematological reactions (leucopenia, agranulocytosis, thrombocytopenia, pancytopenia and haemolytic anaemia) have been reported (Goodman and Gilman, 1975 
